Multiple gene edits produced a living cancer therapy for a desperate case. In 2022 base-edited donor T cells put a child’s resistant leukemia into remission. It showcased layered genome editing in medicine.
Layered edits
Editing was extensive. Several genes were altered to make donor cells usable. Precision mattered.
Off-the-shelf cells
Sourcing shifted. Donor cells replaced the patient’s own. Speed improved.
A remission
The result was dramatic. A resistant leukemia retreated. Hope returned.
Single case
Scope was narrow. One patient’s outcome cannot generalize. Trials are needed.
Editing precision
Safety hinges on accuracy. Unintended edits are a concern. Monitoring is careful.
A broader program
Ambition is large. The approach targets other cancers. Development continues.
The bottom line
Base-edited donor T cells drove a child’s resistant leukemia into remission in 2022, showcasing layered genome editing. It is a single case requiring trials. The approach is being extended to other cancers.
